SCHEMBL4059836

SCHEMBL4059836

CC(Cc1nc2ncc(-c3ccco3)cc2[nH]1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
ADORA2A P29274 4/20 0.34
ADORA1 P30542 3/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2B P29275 1/20 0.34
IKBKE Q14164 1/20 0.34
TBK1 Q9UHD2 1/20 0.34
ALPL P05186 1/20 0.34
MAPK1 P28482 1/20 0.34
PDE10A Q9Y233 3/20 0.34
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
NISCH Q9Y2I1 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK10 P53779 1/20 0.33
AXL P30530 1/20 0.33
PDPK1 O15530 1/20 0.33
EGFR P00533 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053712 0.85 NOS3 (0.52) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL13608690 0.83 AXL (0.38) ADORA2AADORA1ADORA3ADORA2BALPL
SCHEMBL4054333 0.81 GAA (0.43) NOS3NOS1NOS2PDE10AALDH1A1
SCHEMBL4060650 0.80 NOS3 (0.49) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4055225 0.79 NOS1 (0.42) NOS3NOS1NOS2ADORA2APDE10A
SCHEMBL4051951 0.79 SMN1; SMN2 (0.47) NOS3NOS1NOS2IKBKETBK1
SCHEMBL4050337 0.78 ALDH1A1 (0.53) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4061234 0.78 NOS3 (0.45) NOS3NOS1NOS2ADORA2AADORA1
SCHEMBL4052395 0.78 RAB9A (0.46) NOS3NOS1NOS2MAPK1ALDH1A1
SCHEMBL4053662 0.77 NOS3 (0.44) NOS3NOS1NOS2ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.